<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120428009576N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-03</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>comparative evaluation of the effect of misoprostol vaginal suppository to vaginal misoprostol with nitroglycerine in rippening of cervix in term pregnancy reffered to kowsar hospital</public_title>
      <acronym></acronym>
      <scientific_title>comparative evaluation of the effect of vaginal misoprostol to vaginal misoprostol with nitroglycerine in cervix rippening in pregnant women at term referred to Kowsar hospital of Qazvin province</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>106</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/31916</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to randomized groups based on the demographic data and then divided into two groups. The paired numbers are then assigned to the misoprostol group and the individual numbers to the misoprostol group together with nitroglycerin. Then by moving one of the numbers, we move in a predetermined direction.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Ripening cervix.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: In the dual drug group, misoprostol is given at a dose of 25 micro grams vaginal with  nitroglycerin 40 mg vaginal and after 6 hours, the cervix is examined for Bishop Score, and in the case of inappropriate cervix, 25 micrograms of the next misoprostol is administered up to a maximum of 4 doses. Intervention 2: Second intervention group: In the single dose group, misoprostol is given with a dose of 25 micrograms of vaginal and after 6 hours, the cervix is examined for Bishop Score in case of inappropriate cervix, 25 micro grams of misoprostol is administered up to a maximum of 4 doses.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information is the most commonly used questionnaire, which is a statistical analysis

When:
Starting 6 months after publication

To whom:
Only available for people working in academic institutions

Conditions:
Path analysis

Where to obtain:
Dr Ezzatsadat Hajseyyedjavadi

How to obtain:
The email will be submitted to the project promoter at the discretion of the information.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Rafiee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar Blvd, Qazvin, Iran</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1317634156</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>dr_seidjavadi@yahoo.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ezzatsadat Hajseyedjavadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar Blvd, Qazvin, Iran</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1317634156</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>dr_seidjavadi@yahoo.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primigravida
Gestational age&gt;=37 week
Bishop score&lt;=4
Cephalic presentation
Reactive NST
Viable fetus
Estimated weight before 4 kilogram
Amniotic fluid &gt;5
Singleton</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Surgery on the uteus or previous cesarean section
chronic hypertension and preeclampsia
uterine contractions
The presence of heart, kidney and liver disease
rapture of membrane
IUGR
Suspected embryonic anomalies
chorioamnionitis
Fever above 38 ° C
polyhydramnios
Pre-delivery hemorrhage
fetal distress</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>-</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: In the dual drug group, misoprostol is given at a dose of 25 micro grams vaginal with  nitroglycerin 40 mg vaginal and after 6 hours, the cervix is examined for Bishop Score, and in the case of inappropriate cervix, 25 micrograms of the next misoprostol is administered up to a maximum of 4 doses.</i_keyword>
      <i_keyword>Second intervention group: In the single dose group, misoprostol is given with a dose of 25 micrograms of vaginal and after 6 hours, the cervix is examined for Bishop Score in case of inappropriate cervix, 25 micro grams of misoprostol is administered up to a maximum of 4 doses.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The duration of cervical ripening until delivery. Timepoint: 6 and 12 hours. Method of measurement: Vaginal exam.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of taking the drug until the onset of the active phase of labor. Timepoint: every 2 hours. Method of measurement: Vaginal exam.</sec_outcome>
      <sec_outcome>Duration of taking drug until delivery. Timepoint: every 2 hours. Method of measurement: Vaginal exam.</sec_outcome>
      <sec_outcome>Duration of the fist phase of labor. Timepoint: every 2 hours. Method of measurement: Vaginal exam.</sec_outcome>
      <sec_outcome>Duration of the second phase of labor. Timepoint: every 1 hours. Method of measurement: Vaginal exam.</sec_outcome>
      <sec_outcome>Reach to vaginal delivery. Timepoint: After delivery. Method of measurement: Date sheet.</sec_outcome>
      <sec_outcome>Type of delivery. Timepoint: After delivery. Method of measurement: Date sheet.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-05-16</approval_date>
        <contact_name>Ethics committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Bahonar Blvd, Qazvin, Iran Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
